(3) Melnikova, I, Pain Market, Nature Reviews Drug Discovery, Volume 9, 589-90 ( August 2010) and H. Lullmann et. al., 2005, "Color Atlas of Pharmacology".SOURCE Nektar Therapeutics
Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.